Latest Product Launches News

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

OMG Group has significantly expanded its Oat Milk Goodness PrOATein ready-to-drink range to nearly 1,000 Woolworths stores nationwide, backed by a recent $2 million capital raise and plans for new product launches.

The Calmer Co. reports a significant operational turnaround in H2 FY25, with sales momentum building through July and August, driven by cost reductions and new product launches in the US market.

Atomos Ltd reported a 9% revenue decline in FY25, impacted by US tariffs and weak sales of new products, but has aggressively cut costs and revamped its strategy to fuel growth in FY26.

HALO Technologies reports a significantly improved half-year net loss and secures verbal FCA approval for its UK platform, while preparing to launch Managed Funds in Australia.

FirstWave Cloud Technology reports a significant reduction in losses for FY25, driven by operational restructuring and new AI initiatives, while setting sights on Latin American expansion.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.

Atomos Ltd reported a 9% revenue decline to $32.7 million for FY25 but improved its loss after tax by 35%, driven by cost restructuring and tighter expense control amid challenging market conditions.

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.